Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating the addition of ASTX727 (cedazuridine/decitabine) to paclitaxel and pembrolizumab for metastatic or unresectable triple-negative b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer
• Unresectable Triple-negative Breast Cancer

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)
• PACLITAXEL (PACLITAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Status: RECRUITING